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Cancers are rarely caused by single mutations, but often develop based on the combined
effects of multiple mutations. For most cells, the number of possible cell divisions is lim-
ited due to various biological constrains, as for example progressive telomere shortening,
cell senescence cascades or a hierarchically organized tissue structure. Thus, the risk of ac-
cumulating cells carrying multiple mutations is low. Nonetheless, many diseases are based
on the accumulation of such multiple mutations. We model a general, hierarchically orga-
nized tissue by a multi compartment approach, allowing any number of mutations within a
cell. We derive closed solutions for the deterministic clonal dynamics and the reproductive
capacity of single clones. Our results hold for the average dynamics in a hierarchical tissue
characterized by an arbitrary combination of proliferation parameters. We show that hier-
archically organized tissues strongly suppress cells carrying multiple mutations and derive
closed solutions for the expected size and diversity of clonal populations founded by a sin-
gle mutant within the hierarchy. We discuss the example of acute lymphoblastic childhood
leukemia in detail and find a good agreement of our predicted results and recently observed
clonal diversities in patients. This result can contribute to the explanation of very diverse
mutation profiles observed by whole genome sequencing of many different cancers.
Keywords: Cancer, clonal extinction & diversity, mathematical modeling
1. Introduction
The lifespan of most cells in biological organisms is limited and usually the life expectancy
of the organism exceeds this time by orders of magnitudes [1, 2]. As cells are continuously
lost, mechanisms to replenish the cell pool evolved in organisms, enabling sustained cell
production during life time [3]. Often this is realized by hierarchically organized tissue
structures. At the root of the hierarchy are few tissue specific stem cells, combining two
properties, self renewal and differentiation potential [4]. During cell proliferation, cells
differentiate and become increasingly specialized to perform specific functions within the
hierarchy. After some differentiation steps the complete spectrum of functional cells can
be obtained [5–10]. A prominent example is the hematopoietic system [6–11], but other
tissues as for example skin [12, 13] or colon [14] are also hierarchically organized.
A large number of cell divisions are indispensable to life, however, they are unavoid-
ably accompanied by mutations. Typically, these cells are washed out of the hierarchy and
thus, especially if they arise in relatively differentiated cells, the associated mutations are
lost in the long run [10, 15]. But cells with multiple mutational hits might persist for a long
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time, causing the risk of the accumulation of additional mutations during cell proliferation,
which can ultimately lead to cancer. Although some cancers seem to be caused by single
mutation hits, for example the BCR-ABL translocation occurring in stem cells in chronic
myeloid leukemia [16] or the PML-RARA translocation occurring in more differentiated
cells in acute promyelocytic leukemia [17], they are rare. The majority of cancers are trig-
gered by at least a handful of mutations [18–20]. The recent progress in genome sequencing
techniques allowed in some cases the classification of cancer initiating mutations, in other
cases the underlying mutations remain unknown [21]. However, many of these studies re-
veal a very diverse mutation landscape, indicating the existence of several cancer initiating
driver mutations and additional alterations that have a small or even no impact on cancer
development, so called passenger mutations [22–29]. The precise impact of passenger mu-
tations on cancer progression is still under discussion, but the typical assumption is that
they are neutral and do not affect the proliferation properties of cells [30, 31]. In partic-
ular, this holds for synonymous mutations that do not have any consequences on protein
structure or function [32].
In mathematical and computational approaches, compartment models are frequently
used to describe cell dynamics in hierarchically organized tissue structures. Many of these
studies investigate effects of stem cell mutations and related clinical implications, see for
example [6, 8, 33–36]. Also stochastic effects of tissue homeostasis are analyzed [37–39],
highlighting, that cancer driving mutations can in principle disappear by chance (stochas-
tic extinction). The interplay of stem cell and progenitor cell mutations and their impact
on cancer initiation are discussed [40] and game theoretical approaches allow to model
evolutionary aspects of tissue homeostasis and inter cell competition [41, 42]. Often, these
studies investigate the effects of cells carrying one or very few specific mutations and as-
sume either constant population size or only minimal hierarchies.
Here, we focus on the presence of cells carrying multiple mutations within a hierarchi-
cally organized tissue. We show mathematically, that the hierarchical organization strongly
suppresses cells carrying multiple mutations and thus reduces the risk of cancer initiation.
Closed solutions for the total cell population that arises from a single (mutant) cell are
derived and from this the expected diversity of the mutation landscape and the clonal size
can be described. This enables a better understanding of the expected diversity in mutation
landscapes that are observed in both healthy and cancerous tissues.
(a) Mathematical model
The hierarchical tissue organization is typically modeled by a multi compartment ap-
proach [6, 10]. Each compartment represents a certain differentiation stage of cells. At the
root of the hierarchy are stem cells ensuring a continuous influx of cells. A proliferating
cell in compartment i divides and the two daughter cells differentiate and migrate into the
next downstream compartment (i+ 1) with probability ε, increasing the downstream com-
partment by 2 cells, mutates with probability u or self renews within its own compartment
with probability 1−ε−u. Mutated cells stay in the hierarchy. If a mutated cell proliferates,
it differentiates with probability ε into the next downstream compartment, it self renews
with probability 1−ε−u, or it mutates with probability u again, leading to a cell with two
(or more) mutations. All possible outcomes of a cell proliferation are depicted in figure 1.
The direction of the arrows point towards the accessible cell states and the labels give the
transition probabilities. We allow arbitrary parameters and introduce εki as differentiation
probability of cells in compartment i carrying k mutations. Asymmetric cell divisions are
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not explicitly implemented, as they can be absorbed in the differentiation probabilities on
the population level. The fate of a cell’s offspring is determined based on the probabilities
εki . Cells proliferate with a rate ri in each compartment i. Usually cells in upstream com-
partments proliferate slow and cell proliferation speeds up in downstream compartments
(i.e. ri < ri+1). This general framework is very flexible and different tissue structures can
be represented.
(b) Stochastic individual based simulations
We implement individual based stochastic simulations of the cell dynamics in hierar-
chically organized tissue structures. We utilize an implementation of the Gillespie algo-
rithm [43, 44]. Originally introduced to simulate chemical reactions, it allows us to repro-
duce exact stochastic trajectories of the system. Each cell has an individual representation.
Thus, the complete clonal history of cells within the hierarchy can be recorded. If a cell is
chosen for reproduction (determined by the Gillespie method), it either differentiates, self
renews, or mutates according to the probabilities εki and u. The parameters of the simulated
system are described below and chosen to represent human hematopoiesis.
(c) The hematopoietic system
In the following we focus on the hematopoietic system. There, about 400 stem cells
replenish the hematopoietic cell pool [45, 46]. Each stem cell divides approximately once
a year [45, 47]. Cell proliferation is assumed to increase exponentially ri = γir0, with
γ = 1.26 and r0 corresponds to the proliferation rate of stem cells. The differentiation
probability is assumed to be constant, ε = 0.85, for all non stem cell compartments and in
total i = 31 compartments are needed, to ensure a daily bone marrow output of approxi-
mately 3.5× 1011 cells [6, 10].
2. Results
(a) Time continuous dynamics of multiple mutations
We describe the deterministic dynamics of a cell population within a hierarchically or-
ganized tissue structure, that initially carries no mutation. A cell may commit further into
the hierarchy (differentiate), mutate, or self renew itself. This occurs with probability ε, u
and 1−ε−u, respectively. In figure 1 a schematic representation of the resulting hierarchi-
cal structure is shown. Compartments to the right represent downstream compartments of
more specialized (differentiated) cells, while compartments to the bottom represent states
of cells, that accumulated an additional mutation. During one cell division, a cell either
mutates and moves one compartment to the bottom, differentiates and produces two cells
in the next downstream compartment to the right, or self renews and produces an addi-
tional cell within its original compartment. This leads to an expansion of clonal popula-
tions within the hierarchy, that potentially accumulates several (distinct) mutations during
the differentiation process. This is schematically shown in figure 2.
The above transition probabilities can be used in an individual based stochastic simu-
lation. In the following, we provide a deterministic description of the average dynamics of
cells carrying multiple mutations in such hierarchical structures. Thus, we describe the dy-
namics by transition rates instead of transition probabilities, but only averages enter in our
description. By doing so, we neglect certain effects, such as stochastic extinction of cells.
Article submitted to Royal Society
4 BW, DD, AT
However, the approach allows us to investigate the averages of the underlying stochastic
simulations.
Assume that in compartment i there are Nki (t) cells carrying k mutations at time t.
The number of these cells increases due to influx from the upstream compartment at a rate
2ri−1εki−1, mutations with a rate riu and self renewal at a rate ri
(
1− εki − u
)
. Cells are
lost either by mutation at a rate riu, or differentiation at a rate riεki . The deterministic de-
scription of the hierarchical compartment model becomes a system of coupled differential
equations [10], given by
N˙ki (t) =
{
ri
(
1− 2αki
)
Nki (t) + 2riε
k
i−1N
k
i−1 (t) k = 0
ri
(
1− 2αki
)
Nki (t) + 2riε
k
i−1N
k
i−1 (t) + riuN
k−1
i (t) k > 0.
(2.1)
Here αki = ε
k
i + u denotes the probability that a cell with k mutations leaves compartment
i. Typically, αki is very close to ε. A model for stochastic cell dynamics in the stem cell
compartment for neutral and non neutral mutations can be found in [39, 48]. In that paper,
the stochastic Moran process is used to investigate the extinction and fixation probabilities
of stem cell mutations. The deterministic stem cell driven cell replenishment in hierar-
chical tissues is studied in detail in [10]. However, in that prior work, the effects arising
from additional mutations were neglected. Here we focus on non stem cell driven clonal
dynamics. We explicitly allow for an arbitrary number of mutational hits at any stage of
the hierarchy, but we neglect a continuous influx of mutated cells from the stem cell level.
This assumption gives the condition Nk0 (t) = 0. The initial condition
Nki (0) =
{
n0 i = 1 k = 0
0 otherwise,
(2.2)
corresponds to initially n0 cells in compartment 1 carrying no mutation. One can think of
a neutral marker approach, where one cell in the hierarchy is genetically marked, and one
considers the clonal population arising from this marked cell [49]. Although we neglect
a continuous influx of mutated cells from the stem cell compartment, stem cell mutations
can be implemented indirectly. Our approach allows for altered cell proliferation properties
of the founder cell, potentially derived by a mutation at the stem cell level. For a constant
differentiation probability, i.e. the case where all αki and all ε
k
i are identical, equation (2.1)
can be solved recursively. The number of cells in compartment i carrying no mutation
changes in time as
N0i (t) = n0
(2ε)
i−1
(2α− 1)i−1
i−1∏
j=1
rj
 i∑
l=1
erl(1−2α)t
i∏
h=1
h6=l
(rh − rl)
. (2.3)
The solution can also be derived recursively for cells carrying k mutations in compartment
i and becomes
Nki (t) = n0
k∑
h=0
uk−hghi
k!
(2ε)
i−1
(2α− 1)i+h−1
i−1∏
j=1
rj
 i∑
l=1
(rl t)
k−h
erl(1−2α)t
i∏
h=1
h6=l
(rh − rl)
, (2.4)
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where ghi is a combinatoric parameter denoted in 2.5 for cells carrying up to three muta-
tions,
h = 0 h = 1 h = 2 h = 3
k = 0 1
k = 1 1 i− 1
k = 2 1 (i− 1)k i(i− 1)
k = 3 1 (i− 1)k i(i− 1)k (i+ 1)i(i− 1)
(2.5)
If α < 0.5, non stem cells will continuously accumulate in downstream compartments. The
probability of self renewal in this case is larger than the probability of differentiation. This
scenario seems to be realized in certain blood cancers. For example in acute promyelocytic
leukemia an abnormal increase of immature granulocytes and promyelocytes is observed,
resulting from a block of cell differentiation at a late progenitor cell stage [17, 50]. However
these cases are rare.
For α > 0.5, the solution becomes a clonal wave, traveling through the hierarchy in
time. In this case the probability of differentiation is larger than the probability of self
renewal and thus cells progressively travel downstream, see figure 3 as an example. The
cell population founded by a single non stem cell expands within the hierarchy initially,
but gets washed out and vanishes in the long run. This is believed to be true for healthy
homeostasis. For example for the hematopoietic system the differentiation probability was
estimated to be ε = 0.85 [6]. As by far most cell proliferations occur at the progenitor and
more committed differentiation stages, this provides a natural protection of the organism
against the accumulation of multiple mutations, as the survival time of most (non stem cell
like) mutations is finite.
The maximum mutant cell count of the clonal wave and the time to reach this max-
imum can be calculated for the compartment of the mutant origin, in our case the first
compartment. The time is given by
tkmax =
k
(2α− 1) r1 . (2.6)
The time to reach the maximum increases linearly with the number of additional mutations
k. The cell count at the maximum becomes
Nk1 (tmax) =
(uk)
k
k! (2α− 1)k
e−k ≈ u
k
(2α− 1)k
1√
2pik
, (2.7)
where we used the Stirling formula to approximate k!. The maximum scales with uk and
thus decreases exponentially with k. In addition the factor 1/
√
k leads to a further suppres-
sion of the maximum for increasing k. However, the risk of additional mutations depends
not on the maximal cell count, but on the reproductive capacity of a cell line. This repro-
ductive capacity can be captured by the cumulative cell count. The number of cells within
compartment i carrying k mutations produced until time t is given by
mki (t) = riα
k
i
∫ t
0
dsNki (s) , (2.8)
and the reproductive capacity can be derived by taking the time limit to infinity. The general
solution (2.4) allows to carry out the integral exactly by integration by parts. However, the
problem can be tackled from a different perspective, leading to a more transparent solution
of (2.8) that is easier to handle.
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(b) Cell reproductive capacity
We call the cell subpopulation within a compartment i, that is derived by a single
founder cell in an upstream compartment, the reproductive capacity of this founder cell.
This idea directly corresponds to the method of neutral markers. We imagine a genetically
marked cell somewhere in the hierarchy and count the offspring of this cell at any stage of
the hierarchy. This corresponds to the total count of cells with same color in figure 2.
Assume a single cell carrying no mutation in compartment 1. This cell differentiates
with probability ε01 into the next downstream compartment, mutates with probability u or
produces an additional cell in compartment 1 with probability 1− ε01 − u. We first discuss
the probability, that a cell leaves compartment 1 after exactly l cell divisions. A cell can
leave a compartment either by mutation or differentiation, before which the cell has to
undergo l−1 self renewals. Thus, this probability becomes (ε+ u) (1− ε− u)l−1. During
this time, the cell population in compartment 1 derived from this single cell increased to
2l−1 cells, if all daughter cells share the same proliferation probabilities. With this, the
reproductive capacity of a single cell in compartment 1 is on average
m01 =
∞∑
l=0
α01 2
l
(
1− α01
)l
=
{
α01
2α01−1 α
0
1 >
1
2
∞ α01 ≤ 12 .
(2.9)
The sum becomes infinite if α ≤ 0.5, as the probability to produce offspring in the founder
compartment is higher than the probability to leave the compartment. Thus, the cell pop-
ulation continuously increases. Of course, under normal conditions, cells do not have an
unlimited capacity to divide and serial telomere erosion amongst others will impose a phys-
ical limit on the number of divisions a cell can undergo [1, 51]. The biologically more
relevant case is α > 0.5 and cells tend to differentiate into more committed compartments.
In this case, the total number of offspring cells that arise from a single cell (i.e. a clone)
is finite and given by (2.9). The number of cells m0i in compartment i carrying no muta-
tion, increases due to influx of cells via differentiation from compartment i − 1 and the
expansion of these cells due to self renewal in compartment i. Thus, we can write for the
reproductive capacity of cells in compartment i without mutation
m0i = 2
ε0i−1
α0i−1
m0i−1
α0i
2α0i − 1
=
α0i
2α0i − 1
i−1∏
l=1
2ε0l
2α0l − 1
. (2.10)
This can be generalized, and an expression for the reproductive capacity of cells in com-
partment i carrying k mutations can be derived. Cells in compartment i with k mutations
are acquired either by differentiation of cells from compartment i − 1 that carry k muta-
tions, by mutation of cells in compartment i carrying k − 1 mutations, or by self-renewal
of cells already in compartment i and k mutations. With this, we can write
mki =
(
2
εki−1
αki−1
mki−1 +
u
αk−1i
mk−1i
)
αki
2αki − 1
, (2.11)
where the two terms in the bracket represent cells either produced by differentiation or
mutation, multiplied with the self renewal potential of these cells. This recurrence relation
can be solved recursively
mki =
αki
2αki − 1
i∑
l=1
2i−l
u
αk−1l
mk−1l
i−1∏
h=l
εkh
2αkh − 1
. (2.12)
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Since m0i is given by (2.10) one can construct the explicit solution iteratively. Equation
(2.12) allows for arbitrary parameters αki and thus incorporates any mutational induced
change in cell proliferation parameters. However, if αki ≤ 0.5 the sum diverges. Cells with
at least k mutations will accumulate in all compartments downstream i. Note, that equation
(2.12) captures the general deterministic dynamics of a cell lineage founded by a single cell
somewhere in the hierarchy. We are especially interested in the case where this founder
cell carries critical, potentially cancer driving mutations that will allow us to address the
expected number of mutations arising in this mutant clone. In addition, also the probability
of obtaining such a critical mutational hit can be investigated. Not that equation (2.12) is
based on a fully deterministic picture. But even if a cell accumulated a critical number of
mutations, it might still go extinct du to stochastic effects, see for example [19, 37, 39].
In the following, we discuss the general solution of equation (2.12) for mutations that are
neutral relative to the founder cell.
(c) Reproductive capacity of neutral mutants
We call a mutation neutral if the reproductive capacity of the mutant and the founder
cell is equal. In the former subsection we have shown, that the reproductive capacity of a
cell depends on its differentiation probability ε and its mutation rate u, but interestingly it
is independent of the reproduction rate r. Therefore the clonal lineage and the number and
type of mutations that arise from a single founder cells do not depend on the proliferation
rates of the founder cells. However, the time to reach those states of course depends on
r. Therefore, although two mutations lead to the same outcome, this might occur on dis-
tinct time scales, with observable differences in the progression of diseases. Nonetheless,
our definition of neutral mutations only requires constant differentiation probabilities and
mutation rates relative to the founder cell. This assumption allows us to write εki = εi and
thus the number of parameters is reduced from (k + 1) i + 1 for the general case to i + 1
for the neutral case. This number can be reduced to two parameters u and ε, if a constant
differentiation probability for all non stem cell stages is assumed, εi = ε. This simplifies
the evaluation of the recurrence relation (2.12) significantly. The reproductive capacity mki
of neutral mutations in compartment i carrying k mutations becomes
mki = α
uk
k!
(2ε)
i−1
(2α− 1)i+k
k∏
l=1
(i+ l − 1) = αuk (2ε)
i−1
(2α− 1)i+k
(
i+ k − 1
k
)
. (2.13)
Mutants carrying k mutations are suppressed by a factor uk and thus are rare in early
differentiation stages. The number increases exponentially for downstream compartments,
and a significant load of cells carrying few mutations can be observed in late differentiation
stages, see figure 4.
Equation (2.13) reveals interesting properties of hierarchical tissue structures. The ratio
of cells carrying k mutations to cells carrying k − 1 mutations in compartment i is
mki
mk−1i
=
u
2α− 1
(
1 +
i− 1
k
)
. (2.14)
The ratio increases with compartment number, but the increase becomes flatter for in-
creasing k. The compartment structure leads to an additional suppression of cells carrying
multiple mutations and thus is a protection mechanism against cancer initiation. The ratio
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is constant for i = 1, the compartment of the mutant origin. The protection mechanism
affects downstream compartments only.
On the other hand, the scaling properties for more differentiated cells show interesting
properties also. The ratio of cells with k mutations in compartment i + 1 to cells with k
mutations in compartment i is given by
mki+1
mki
=
2ε
2α− 1
(
1 +
k
i
)
. (2.15)
The increase of cells is constant for cells carrying no mutations k = 0. It increases with k,
but is suppressed within the hierarchy by the factor of 1/i.
(d) Number of distinct neutral mutations
So far, we have discussed the reproductive capacity of cells. However, we did not dis-
tinguish between different mutations, but grouped together cells with an equal number of
mutations. Often experimental studies focus on mutation landscapes, investigating the vari-
ation in clonal loads in healthy and sick individuals. Our approach allows us to estimate the
expected number of distinct mutations that arise from a single founder cell, corresponding
to the count of distinct symbols with same color in figure 2.
Let us assume that every mutation event is unique. Thus, we neglect the possibility that
the same mutation is derived twice independently. The diversity in compartment i increases
either by additional mutations of cells in compartment i, or differentiation of clones from
compartment i − 1 into compartment i. Assuming a differentiation probability ε > 0 the
expected diversity nk+1i of cells with k + 1 mutations in compartment i is
nk+1i = u
i∑
j=1
mkj = αu
k+1
i∑
j=1
(2ε)
j−1
(2α− 1)j+k
(
j + k − 1
k
)
. (2.16)
As an example, if we use the parametrization of the hematopoietic system, ε = 0.85 and
u = 10−6, we find approximately n131 ≈ 30 distinct single mutations in compartment
31, that were derived from the clonal progeny of a single founder cell in compartment 1.
But the founder cell by chance could carry a mutation, that changes their cell proliferation
parameters. For example, the differentiation probability of the founder cell could change
to ε = 0.75. In this case, equation 2.16 estimates 28000 distinct mutations derived from
this single founder cell. We note, that the above change of the differentiation probability
from 0.85 to 0.75 is sufficient to explain the manifestation of chronic myeloid leukemia in
otherwise healthy adults [38, 52]. However, equation (2.16) represents an average and in
individual cases fluctuations, caused by stochasticity are expected. But also small changes
in ε or u influence the expected diversity significantly. A linearized error analysis [53]
reveals the dependency of (2.16) on the uncertainties of u and ε, which is given by
∆nk+1i =
i∑
j=1
(2ε)
j−1
(2α− 1)j+k+1
(
gεj + g
u
j
)(j + k − 1
k
)
, (2.17)
with gεj = u
k+1|2α (1− j − k)− 1|∆ε and
guj = u
k|(k+1)ε (2ε− 1)+u (2 (k − j + 3)) ε− k − 2)+2u2 (2− j) |∆u. If we assume
∆u = 10−7 and ∆ε = 0.01 the uncertainty given by (2.17) becomes ∆n131 ≈ 35, where
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the individual error contributions in u and ε are 7 and 28 respectively. Especially note the
strong dependency on ∆ε. If we choose ∆ε = 0.05, a deviation, that might be difficult
to detect in vivo, one gets ∆n131 ≈ 150. Thus, small variations in ε lead to significant
differences in the expected diversity of clonal populations, one aspect that might contribute
to the explanation of the observation of very diverse mutation landscapes. Note also, that
an increasing mutation rate ∆u = 10−6 gives ∆n131 ≈ 65. Of course, higher mutation rates
increase the expected diversity of clonal populations. However, a higher mutation rate (or
genomic instability) is neither the exclusive nor necessarily the dominant underlying cause
of the diversity in the mutation landscape that is observed.
(e) Example: clonal diversity in acute lymphoblastic leukemia
Let us now consider a specific example using data from childhood acute lymphoblas-
tic leukemia (ALL). The most common chromosomal abnormality in this disease is the
t(12;21) translocation that results in the fusion gene ETV6-RUNX1 (also known as
TEL/AML1). There is evidence that this mutation often arises in utero. This has been con-
firmed to be the case in at least one pair of monozygotic twins [54]. This mutation is a
founder mutation and is considered to be critical for the disease. Cells that express this fu-
sion gene appear to have a higher self-renewal and enhanced survival compared to normal
cells [54, 55]. In our model, enhanced self-renewal implies a reduced differentiation prob-
ability for the cells carrying the mutation (ε < 0.85). Recently, Ma et al. performed whole
genome sequencing on leukemic cells isolated from two pairs of monozygotic twins. In
one pair of twins, the initial event occurred in utero since the ETV6-RUNX1 fusion was
shared by both siblings [56]. They found that the incidence of non-synonymous single nu-
cleotide mutations between the samples ranged from 708 to 1237 [56]. These mutations
must have occurred after the founder mutation and independent of each other. The time
from the putative appearance of the shared ETV6-RUNX1 mutation and disease was 48 to
55 months. The second pair of monozygotic twins shared a mutation in NF-1, and the time
to diagnosis of ALL was 72 to 77 months after birth. The tumors in these two children had
949 to 975 unique non synonymous single nucleotide mutations. Using these constraints
and an estimate of 10%-75% cancer cells at diagnosis, unchanged proliferation rates as
well as N0 = 100 [57], we use equation (2.4) to estimate the differentiation probability ε
for the mutant cells, which is then in the range of 0.78 to 0.81, ie. only slightly lower than
that of normal cells. Based on equation (2.4), it takes approximately 50 to 80 months to
reach this load. We further predict a range of 350 to 2600 distinct mutations by utilizing
equation (2.16), assuming a mutation rate of u = 10−6 and the above range of differentia-
tion probabilities. Thus, we expect slightly more distinct mutations than found in patients.
But some of those theoretically predicted clonal populations are small and may escape de-
tection. For example, if we neglect mutations, that occur during the last differentiation step
of cells in compartment 30 to 31 (expected to be small cell populations), we predict only
150 to 950 distinct mutations. Clearly, the model as presented can explain the large number
of passenger mutations that can be expected in a typical patient with ALL and likely other
types of leukemia.
3. Discussion
The accumulation of multiple mutations in cells is considered to be critical for cancer ini-
tiation. However, mutations unavoidably accompany cell proliferation and thus cancer can
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potentially occur in any multicellular organism. Hierarchical tissue structures contribute
to the protection against such mutations. So far, the suppression of single mutations in hi-
erarchical tissue structures has been the focus. Here, we have shown that in addition, the
risk of the accumulation of multiple mutations is dramatically reduced by a hierarchical
tissue organization. The cell population is divided into few slow proliferating stem cells
and many faster proliferating progenitor cells. Stem cells have an almost infinite cell re-
productive capacity, but the manifestation of a critical mutational load often exceeds an
organisms expected natural life time. Progenitor cells proliferate faster, but their reproduc-
tive capacity usually is limited and thus they give rise to clonal waves traveling through the
hierarchy. Still both cases can be observed. There are cancers that presumably originate
from stem cell mutations for example chronic myeloid leukemia, and there are cancers
that originate in later stages of hematopoiesis, for example acute promyelocytic leukemia
and various other subtypes of acute myeloid leukemia [17]. Understanding the clonal dy-
namics for both cases is of importance. Here, we have focused on the accumulation of
non stem cell driven mutations in hierarchically organized tissues. We arrived at closed
solutions for the clonal waves traveling through the hierarchy. From this the reproductive
capacity of cells can be deduced. This allows us to predict the expected risk to acquire
any number of mutations from one single cell, given the proliferation properties of this
cell. We derived equations that allow the quantitative classification of multiple mutations
in hierarchically organized structures, highlighting the strong suppression of clones car-
rying multiple mutations by this architecture. Although we neglected clonal competition
over limited resources, such as cytokines or nutrients, we expect the model to capture gen-
eral patterns of clonal expansions in hierarchically organized tissues and serving as a null
model. Moreover, those cancer cells that divide independently of proliferation signals (for
example due to mutated tyrosine kinases) escape such a competition.
Another important question emerged more recently with the accessibility of whole
genome sequencing technology. These techniques revealed very complex and diverse mu-
tation landscapes for many different cancers, with the classification of driver and passenger
mutations as the final goal. Knowing the exact driver mutations might help to understand
the properties of specific cancer cells, allowing the development of effective treatment
strategies. A promising example is the design of molecularly targeted agents such as the
various tyrosine kinase inhibitors (Imatinib, Nilotinib etc) to treat patients with chronic
myeloid leukemia. These molecules specifically bind to kinase domains, encoded by the
BCR-ABL oncogene and strongly suppress the proliferative capacity of these cells [58–
60]. Our work can contribute to this question by predicting the average number of distinct
neutral (passenger) mutations, acquired from a single cell at any stage of the hierarchy. This
approach directly corresponds to the method of a neutral marker. The genetically marked
cell represents the founder cell of the clonal population and one follows the offspring of
this founder cell throughout the hierarchy. This enables the prediction of the size and the
variability of the clonal population. For example, in normal hematopoiesis, we expect cells
to have a differentiation probability of ε = 0.85, leading to approximately 30 distinct sin-
gle mutations (subclones) in adult cells, acquired from this single cell. If this founder cell
acquired a mutation, that changed the differentiation probability to ε = 0.75 by chance,
the expected number of distinct single mutations increases to approximately 28000.
We have shown how even a slight change in the self-renewal probability of progenitor
cells can lead to substantial differences in the number of passenger mutations observed in
ALL. This likely holds true for other malignancies. In acute promyelocytic leukemia, apart
from the t(15;17) that is a critical event in the origin of this disease (akin to the ETV6-
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RUNX1 discussed above for ALL), approximately 440 non synonymous single nucleotide
mutations were found that were unique to the tumor clone [21]. Interestingly, it is highly
likely that the cell of origin of APL is downstream (a progenitor cell) of the cell of origin
of ETV6-RUNX1 driven ALL and this may, in part, explain the less diverse mutational
landscape reported in APL compared to ALL and would fit well with our model. Of course,
any genomic instability will further increase the repertoire of passenger mutations that is
observed in any given tumor.
We also note, that the effect of a specific mutation on a cell needs not be large for the ef-
fect to spread throughout the tumor. Tissue architecture and dynamics as in hematopoiesis
serve as a deterrent against the accumulation of mutations, in particular multiple mutations
occurring in one cell. Once a driver mutation appears, if this changes either the self-renewal
of the cell or the mutation rate, then the appearance of many passenger mutations becomes
inevitable in such an architecture due to the amplification of cells that occurs. Thus, a minor
change in the differentiation probabilities that might be difficult to detect in vivo drastically
changes the expected number of passenger mutations that would be observed. Concomi-
tantly, this will increase the risk of acquiring mutations in ’driver genes’ and so lead to
malignancy. However, if the initiation of disease requires several co-occurring mutations,
a hierarchical tissue structure is a powerful mechanism of tumor suppression.
B.W. and A.T. thank the Max Planck Society and the Emmy-Noether program of the German Re-
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Figure 1. Schematic representation of the compartment structure of multiple mutations and corre-
sponding transition rates. The top compartments (blue) contain cells carrying no mutation. The bot-
tom compartments (red) contain cells carrying one mutation. Compartments to the right represent
more specialized cell stages and arrows transition probabilities, where ε denotes the differentiation
probability, u the mutation rate of cells and αki = ε
k
i +u. Initially no mutated cells are present in the
hierarchy. We then ask, how many cells are acquired from the founder compartment (top left) and
investigate how many cells with k mutations are on average expected at any stage of the hierarchy.
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Figure 2. Clonal expansion within a hierarchically organized tissue. Cell proliferation is driven by
a few slow dividing stem cells, giving raise to faster dividing progenitor cells. After some differ-
entiation steps the mature tissue cells are obtained. Initially cells have no mutations, but mutants
can arise and expand within the hierarchy. These cells either vanish or gain an additional mutation,
which again potentially spreads within the hierarchy. Different colors code for a different number of
mutations, whereas different shapes indicate different mutations.
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Figure 3. A Number of cells carrying no mutation in compartments 1 to 31 arising from compartment
1 containing 1000 cells. Lines show equation (2.3), with parameters n0 = 1000, ε = 0.85, γ = 1.26,
u = 10−6 and r0 = 1/400. Cells are more likely to differentiate than to self renew and thus
progressively travel into more committed compartments. Initially, the cell count increases, but cells
get washed out in the long run. The time scale is determined by the number of stem cell divisions. A
stem cell is assumed to divide once a year, thus after 400 stem cell divisions a year passed. B Count
of cells carrying zero to three mutations in compartment 31, given by equation (2.4). We used same
parameters as in A. Cells carrying multiple mutations are exponentially suppressed.
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Figure 4. A Number of cells without mutations in compartments 1 to 5, arising from a single cell
in compartment 1. Lines are equation (2.8), symbols are averages with corresponding standard de-
viations over 103 independent runs of stochastic individual based computer simulations and squares
are equation (2.13). Parameters are n0 = 1, ε = 0.85, γ = 1.26, u = 10−6 and r0 = 1/400. B
Reproductive capacity of a single founder cell in compartment 1. Shown is the number of cells with
0 to 4 mutations in the first 31 compartments, acquired from a single cell in compartment 1. Symbols
are numerical solutions of (2.8) in the limit of infinite time and lines are equation (2.13). The repro-
ductive capacity increases exponentially for increasing compartment number. Cells carrying multiple
mutations are strongly suppressed within a hierarchical tissue structure, see equation (2.14).
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